<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514746</url>
  </required_header>
  <id_info>
    <org_study_id>JEV07</org_study_id>
    <secondary_id>PR-15036</secondary_id>
    <nct_id>NCT02514746</nct_id>
  </id_info>
  <brief_title>Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose</brief_title>
  <official_title>Assessment of Long Term Immunogenicity of Japanese Encephalitis Live Attenuated SA-14-14-2 Vaccine in Previously Vaccinated Bangladeshi Children and Antibody Response and Safety to a Booster Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to understand the persistence of the Japanese encephalitis (JE) antibody&#xD;
      response in previously vaccinated children. The proposed study will enrol Bangladeshi&#xD;
      children who had previously participated in a lot to lot consistency study (JEV05;&#xD;
      NCT01567865) of JE live attenuated SA 14-14-2 vaccine (CD-JEV).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants previously immunized with CD-JEV (Clinical Trials identifier: NCT01567865,&#xD;
      JEV05) will have serum collected three and four years after initial vaccination to assess&#xD;
      long-term immunogenicity. Four years after receiving the initial dose of CD-JEV, eligible&#xD;
      participants will be vaccinated with a second subcutaneous dose of CD-JEV to assess the&#xD;
      antibody response.&#xD;
&#xD;
      Participants will be monitored for safety for 28 days following receipt of the booster dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2015</start_date>
  <completion_date type="Actual">January 12, 2017</completion_date>
  <primary_completion_date type="Actual">December 15, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprotection Rate Three and Four Years After Initial Vaccination With CD-JEV</measure>
    <time_frame>3 years after initial vaccination (Study Day 1) and 4 years after initial vaccination (Study Day 365)</time_frame>
    <description>Seroprotection rate is defined as the percentage of participants with an anti-Japanese encephalitis (JE) neutralizing antibody titer ≥ 1:10 as measured using a 50% plaque reduction neutralization test (PRNT-50). Seroprotection was assessed at 3 and 4 years after the initial vaccination in Study JEV05, prior to participants receiving a booster vaccination in the current study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer of Anti-JE Neutralizing Antibodies Three and Four Years After Initial Vaccination With CD-JEV</measure>
    <time_frame>3 years after initial vaccination (Study Day 1) and 4 years after initial vaccination (Study Day 365)</time_frame>
    <description>The geometric mean titer (GMT) of anti-JE neutralizing antibodies 3 and 4 years after initial vaccination with CD-JEV in Study JEV05 and prior to receiving the booster vaccination in the current study, measured using PRNT-50.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Rate 7 Days and 28 Days After Booster Dose</measure>
    <time_frame>7 days and 28 days following booster vaccination (Study Days 372 and 393)</time_frame>
    <description>Seroprotection rate is defined as the percentage of study participants with an anti-JE neutralizing antibody titer ≥1:10 assessed using PRNT-50.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Anti-JE Neutralizing Antibodies 7 Days and 28 Days After Booster Dose</measure>
    <time_frame>7 days and 28 days following booster vaccination (Study Days 372 and 393)</time_frame>
    <description>Geometric mean titer of anti-JE neutralizing antibodies measured using PRNT-50.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Rate 7 Days and 28 Days After Booster Dose</measure>
    <time_frame>7 days and 28 days following booster vaccination (Study Days 372 and 393)</time_frame>
    <description>Seroconversion rate is defined as the percentage of study participants with either:&#xD;
For participants who were seronegative at Baseline (defined as anti-JE neutralizing antibody titer of &lt; 1:10 assessed using PRNT-50 at Year 4, prior to booster vaccination): A change in serostatus from seronegative (anti-JE neutralizing antibody titer of &lt; 1:10) to positive (anti-JE neutralizing antibody titer ≥ 1:10)&#xD;
For participants who were seropositive at Baseline (defined as an anti-JE neutralizing antibody titer ≥1:10 assessed using PRNT-50 at Year 4, prior to booster vaccination): a 4-fold increase in anti-JE neutralizing antibody titer relative to Baseline anti-JE neutralizing antibody titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT Ratio of Anti-JE Neutralizing Antibody Titers Between Post-Booster and Pre-Booster Vaccination</measure>
    <time_frame>4 years after the initial vaccination (Study Day 365, pre-booster vaccination) and 7 and 28 days following booster vaccination (Study Days 372 and 393)</time_frame>
    <description>To evaluate the magnitude of the increase in GMTs, the GMT ratio of anti-JE neutralizing antibody titers between post-booster vaccination and pre-booster vaccination was calculated for the following:&#xD;
GMT of anti-JE neutralizing antibodies at 7 days after booster vaccination to the Year 4, pre-booster GMT of anti-JE neutralizing antibodies&#xD;
GMT of anti-JE neutralizing antibodies at 28 days after booster vaccination to the Year 4, pre-booster GMT of anti-JE neutralizing antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Immediate Reactions 30 Minutes Following Booster Vaccination</measure>
    <time_frame>30 minutes following booster vaccination (Study Day 365)</time_frame>
    <description>The number of participants with at least one occurrence of an immediate reaction, including local, systemic, or unsolicited adverse event that occurred within 30 minutes of the booster vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited Local Reactions Occurring Within 7 Days of Booster Vaccination</measure>
    <time_frame>From 30 minutes to 7 days following booster vaccination (Study Day 365 to 372)</time_frame>
    <description>Participants were monitored for local reactions from 30 minutes through 7 days post booster vaccination. Local reactions (at the injection site) included the following:&#xD;
Ecchymosis (bruising)&#xD;
Erythema (redness)&#xD;
Edema (swelling)&#xD;
Induration (hardness)&#xD;
Pain/tenderness&#xD;
Local ecchymosis, erythema, edema, and induration were graded as follows:&#xD;
Grade 1: ≤ 2.5 cm in diameter&#xD;
Grade 2: &gt; 2.5 cm in diameter with &lt; 50% surface area of extremity involved&#xD;
Grade 3: ≥ 50% surface area of extremity involved OR ulceration OR secondary infection OR phlebitis OR sterile abscess OR drainage&#xD;
Grade 4: potentially life-threatening consequences&#xD;
Injection site pain/tenderness were graded as follows:&#xD;
Grade 1: causing no or minimal limitation in use of limb&#xD;
Grade 2: causing greater than minimal limitation of use of limb&#xD;
Grade 3: causing inability to perform usual social or functional activities&#xD;
Grade 4: inability to perform basic self-care OR hospitalization indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Solicited Systemic Reactions Occurring Within 7 Days of Booster Vaccination</measure>
    <time_frame>From 30 minutes to 7 days following booster vaccination (Study Day 365 to 372)</time_frame>
    <description>Participants were monitored for systemic reactions from 30 minutes through 7 days post booster vaccination. Systemic reactions (general signs / symptoms) included the following:&#xD;
Fever&#xD;
Change in eating habits&#xD;
Diarrhea&#xD;
Sleepiness&#xD;
Irritability&#xD;
Unusual crying&#xD;
Vomiting&#xD;
Fever was graded as follows:&#xD;
Grade 1: 37.5 ℃ to 37.9 ℃&#xD;
Grade 2: 38.0 ℃ to 38.4 ℃&#xD;
Grade 3: 38.5 ℃ to 40.0 ℃&#xD;
Grade 4: &gt; 40.0 ℃&#xD;
Change in eating habits, diarrhea, sleepiness, irritability, unusual crying, vomiting were graded as follows:&#xD;
Grade 1: causing no or minimal interference with usual social or functional activities&#xD;
Grade 2: causing greater than minimal interference with usual social or functional activities&#xD;
Grade 3: causing inability to perform usual social or functional activities OR hospitalization indicated&#xD;
Grade 4: inability to perform basic self-care OR medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Unsolicited Adverse Events (AEs) and Serious Adverse Events (SAEs) Within 28 Days Following Booster Vaccination</measure>
    <time_frame>28 days following booster vaccination (Study Days 365 to 393)</time_frame>
    <description>AEs were graded for severity according to the following:&#xD;
Grade 1 (Mild): Symptoms causing no or minimal interference with usual social and functional activities&#xD;
Grade 2 (Moderate): Symptoms causing greater than minimal interference with usual social and functional activities&#xD;
Grade 3 (Severe): Symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated&#xD;
Grade 4 (Potentially life-threatening): Symptoms causing inability to perform basic self-care functions OR medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.&#xD;
Relationship to study vaccine was based on the Clinician's assessment.&#xD;
A serious adverse event is defined as an AE that meets 1 of the following criteria:&#xD;
Death&#xD;
Life-threatening&#xD;
Requires hospitalization or prolongation of existing hospitalization&#xD;
Results in persistent disability&#xD;
Important medical event based on medical judgement</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">561</enrollment>
  <condition>Encephalitis, Japanese</condition>
  <arm_group>
    <arm_group_label>Live Attenuated JE SA-14-14-2 Vaccine (CD-JEV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants previously vaccinated with CD-JEV will receive a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine four years after initial vaccination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine</intervention_name>
    <description>0.5 mL subcutaneous injection</description>
    <arm_group_label>Live Attenuated JE SA-14-14-2 Vaccine (CD-JEV)</arm_group_label>
    <other_name>CD-JEV</other_name>
    <other_name>CD.JEVAX®</other_name>
    <other_name>RS.JEV®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant in JEV05 study (NCT01567865) and received one dose of CD-JEV.&#xD;
&#xD;
          -  Resides in the Matlab or Mirpur study area.&#xD;
&#xD;
          -  At least one parent or guardian willing to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received a second dose of Japanese encephalitis vaccine within the past three years.&#xD;
&#xD;
          -  Received immunoglobulins and/or any blood products within 90 days prior to enrollment.&#xD;
&#xD;
          -  Been diagnosed with a primary or acquired immunodeficiency, including human&#xD;
             immunodeficiency virus (HIV) infection within the past three years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>43 Months</minimum_age>
    <maximum_age>51 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K Zaman, PhD, MPH, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Centre for Diarrhoeal Disease Research, Bangladesh</affiliation>
  </overall_official>
  <results_reference>
    <citation>Zaman K, Naser AM, Power M, Yaich M, Zhang L, Ginsburg AS, Luby SP, Rahman M, Hills S, Bhardwaj M, Flores J. Lot-to-lot consistency of live attenuated SA 14-14-2 Japanese encephalitis vaccine manufactured in a good manufacturing practice facility and non-inferiority with respect to an earlier product. Vaccine. 2014 Oct 21;32(46):6061-6. doi: 10.1016/j.vaccine.2014.09.012. Epub 2014 Sep 18.</citation>
    <PMID>25239483</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 15, 2015</study_first_submitted>
  <study_first_submitted_qc>July 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <results_first_submitted>September 17, 2020</results_first_submitted>
  <results_first_submitted_qc>September 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2020</results_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese Encephalitis Vaccines</keyword>
  <keyword>Flavivirus Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis, Japanese</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02514746/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02514746/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study enrolled Bangladeshi children who had participated in Study JEV05 (NCT01567865) and received a single dose of live attenuated Japanese encephalitis vaccine (CD-JEV).&#xD;
The first visit in this study was 3 years after vaccination in JEV05. At the 2nd study visit, 4 years after initial vaccination, children received a booster dose of CD-JEV.</recruitment_details>
      <pre_assignment_details>Children were analyzed based on whether they received vaccine from the new or old facility in Study JEV05:&#xD;
Group A: Received CD-JEV from new facility in Study JEV05&#xD;
Group B: Received CD-JEV from old facility in Study JEV05</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A: CD-JEV</title>
          <description>Participants previously vaccinated with CD-JEV manufactured in the new facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
        </group>
        <group group_id="P2">
          <title>Group B: CD-JEV</title>
          <description>Participants previously vaccinated with CD-JEV manufactured in the old facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="437"/>
                <participants group_id="P2" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Valid Serology 3 Years Post Primary Dose</title>
              <participants_list>
                <participants group_id="P1" count="437"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Valid Serology 4 Years Post Primary Dose</title>
              <participants_list>
                <participants group_id="P1" count="424"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received CD-JEV Booster Vaccine</title>
              <participants_list>
                <participants group_id="P1" count="424"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="415"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Chronically Ill</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants</population>
      <group_list>
        <group group_id="B1">
          <title>Group A: CD-JEV</title>
          <description>Participants previously vaccinated with CD-JEV manufactured in the new facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
        </group>
        <group group_id="B2">
          <title>Group B: CD-JEV</title>
          <description>Participants previously vaccinated with CD-JEV manufactured in the old facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="437"/>
            <count group_id="B2" value="124"/>
            <count group_id="B3" value="561"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="437"/>
                    <count group_id="B2" value="124"/>
                    <count group_id="B3" value="561"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.7" spread="1.6"/>
                    <measurement group_id="B2" value="47.8" spread="1.4"/>
                    <measurement group_id="B3" value="47.7" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="437"/>
                    <count group_id="B2" value="124"/>
                    <count group_id="B3" value="561"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="291"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Bangladesh</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="437"/>
                    <count group_id="B2" value="124"/>
                    <count group_id="B3" value="561"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="437"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Rate Three and Four Years After Initial Vaccination With CD-JEV</title>
        <description>Seroprotection rate is defined as the percentage of participants with an anti-Japanese encephalitis (JE) neutralizing antibody titer ≥ 1:10 as measured using a 50% plaque reduction neutralization test (PRNT-50). Seroprotection was assessed at 3 and 4 years after the initial vaccination in Study JEV05, prior to participants receiving a booster vaccination in the current study.</description>
        <time_frame>3 years after initial vaccination (Study Day 1) and 4 years after initial vaccination (Study Day 365)</time_frame>
        <population>Enrolled participants with at least one serology result at Year 3 (Day 1) or Year 4 (Day 365), prior to receiving the booster dose (long-term assessment intention-to-treat population [ITT]).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the new facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Group B: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the old facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Participants previously vaccinated with CD-JEV received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate Three and Four Years After Initial Vaccination With CD-JEV</title>
          <description>Seroprotection rate is defined as the percentage of participants with an anti-Japanese encephalitis (JE) neutralizing antibody titer ≥ 1:10 as measured using a 50% plaque reduction neutralization test (PRNT-50). Seroprotection was assessed at 3 and 4 years after the initial vaccination in Study JEV05, prior to participants receiving a booster vaccination in the current study.</description>
          <population>Enrolled participants with at least one serology result at Year 3 (Day 1) or Year 4 (Day 365), prior to receiving the booster dose (long-term assessment intention-to-treat population [ITT]).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="437"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="560"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="560"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="6.8" upper_limit="12.2"/>
                    <measurement group_id="O2" value="9.8" lower_limit="5.7" upper_limit="16.3"/>
                    <measurement group_id="O3" value="9.3" lower_limit="7.2" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="533"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="9.7" upper_limit="16.0"/>
                    <measurement group_id="O2" value="11.9" lower_limit="7.1" upper_limit="19.3"/>
                    <measurement group_id="O3" value="12.4" lower_limit="9.9" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference at Year 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (Group A - B)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.5</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference at Year 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (Group A - B)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.4</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer of Anti-JE Neutralizing Antibodies Three and Four Years After Initial Vaccination With CD-JEV</title>
        <description>The geometric mean titer (GMT) of anti-JE neutralizing antibodies 3 and 4 years after initial vaccination with CD-JEV in Study JEV05 and prior to receiving the booster vaccination in the current study, measured using PRNT-50.</description>
        <time_frame>3 years after initial vaccination (Study Day 1) and 4 years after initial vaccination (Study Day 365)</time_frame>
        <population>Enrolled participants with at least one serology result at Year 3 (Day 1) or Year 4 (Day 365), prior to receiving the booster dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the new facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Group B: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the old facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Participants previously vaccinated with CD-JEV received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Anti-JE Neutralizing Antibodies Three and Four Years After Initial Vaccination With CD-JEV</title>
          <description>The geometric mean titer (GMT) of anti-JE neutralizing antibodies 3 and 4 years after initial vaccination with CD-JEV in Study JEV05 and prior to receiving the booster vaccination in the current study, measured using PRNT-50.</description>
          <population>Enrolled participants with at least one serology result at Year 3 (Day 1) or Year 4 (Day 365), prior to receiving the booster dose.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="437"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="560"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="437"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="560"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="5.5" upper_limit="6.1"/>
                    <measurement group_id="O2" value="5.8" lower_limit="5.3" upper_limit="6.4"/>
                    <measurement group_id="O3" value="5.8" lower_limit="5.6" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="533"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="5.8" upper_limit="6.5"/>
                    <measurement group_id="O2" value="6.0" lower_limit="5.4" upper_limit="6.7"/>
                    <measurement group_id="O3" value="6.1" lower_limit="5.8" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric mean titer ratio at Year 3</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group A/B)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric mean titer ratio at Year 4</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group A/B)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Rate 7 Days and 28 Days After Booster Dose</title>
        <description>Seroprotection rate is defined as the percentage of study participants with an anti-JE neutralizing antibody titer ≥1:10 assessed using PRNT-50.</description>
        <time_frame>7 days and 28 days following booster vaccination (Study Days 372 and 393)</time_frame>
        <population>Participants who received the booster dose of CD-JEV and had at least one serology result 7 days or 28 days after the booster vaccination (ITT booster analysis set).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the new facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Group B: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the old facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Participants previously vaccinated with CD-JEV received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate 7 Days and 28 Days After Booster Dose</title>
          <description>Seroprotection rate is defined as the percentage of study participants with an anti-JE neutralizing antibody titer ≥1:10 assessed using PRNT-50.</description>
          <population>Participants who received the booster dose of CD-JEV and had at least one serology result 7 days or 28 days after the booster vaccination (ITT booster analysis set).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 days after booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="417"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.6" lower_limit="87.5" upper_limit="93.1"/>
                    <measurement group_id="O2" value="94.4" lower_limit="88.3" upper_limit="97.4"/>
                    <measurement group_id="O3" value="91.4" lower_limit="88.7" upper_limit="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days after booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="415"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="95.9" upper_limit="98.9"/>
                    <measurement group_id="O2" value="99.1" lower_limit="95.0" upper_limit="99.8"/>
                    <measurement group_id="O3" value="98.1" lower_limit="96.5" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference at 7 days post booster vaccination</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (Group A - B)</param_type>
            <param_value>-3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.1</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference at 28 days post booster vaccination</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (Group A - B)</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT of Anti-JE Neutralizing Antibodies 7 Days and 28 Days After Booster Dose</title>
        <description>Geometric mean titer of anti-JE neutralizing antibodies measured using PRNT-50.</description>
        <time_frame>7 days and 28 days following booster vaccination (Study Days 372 and 393)</time_frame>
        <population>Participants who received the booster dose of CD-JEV and had at least one serology result 7 days or 28 days after the booster vaccination (ITT booster analysis set).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the new facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Group B: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the old facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Participants previously vaccinated with CD-JEV received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT of Anti-JE Neutralizing Antibodies 7 Days and 28 Days After Booster Dose</title>
          <description>Geometric mean titer of anti-JE neutralizing antibodies measured using PRNT-50.</description>
          <population>Participants who received the booster dose of CD-JEV and had at least one serology result 7 days or 28 days after the booster vaccination (ITT booster analysis set).</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 days after booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="417"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="86.1" upper_limit="113.3"/>
                    <measurement group_id="O2" value="135.4" lower_limit="105.7" upper_limit="173.5"/>
                    <measurement group_id="O3" value="105.4" lower_limit="93.4" upper_limit="118.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days after booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="415"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.2" lower_limit="140.6" upper_limit="173.4"/>
                    <measurement group_id="O2" value="215.4" lower_limit="177.3" upper_limit="261.7"/>
                    <measurement group_id="O3" value="167.0" lower_limit="152.2" upper_limit="183.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric mean titer ratio 7 days after booster dose</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group A/B)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Geometric mean titer ratio 28 days after booster dose</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GMT Ratio (Group A/B)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Rate 7 Days and 28 Days After Booster Dose</title>
        <description>Seroconversion rate is defined as the percentage of study participants with either:&#xD;
For participants who were seronegative at Baseline (defined as anti-JE neutralizing antibody titer of &lt; 1:10 assessed using PRNT-50 at Year 4, prior to booster vaccination): A change in serostatus from seronegative (anti-JE neutralizing antibody titer of &lt; 1:10) to positive (anti-JE neutralizing antibody titer ≥ 1:10)&#xD;
For participants who were seropositive at Baseline (defined as an anti-JE neutralizing antibody titer ≥1:10 assessed using PRNT-50 at Year 4, prior to booster vaccination): a 4-fold increase in anti-JE neutralizing antibody titer relative to Baseline anti-JE neutralizing antibody titer</description>
        <time_frame>7 days and 28 days following booster vaccination (Study Days 372 and 393)</time_frame>
        <population>Participants who received the booster dose of CD-JEV and had at least one serology result 7 days or 28 days after the booster vaccination (ITT booster analysis set).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the new facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Group B: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the old facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Participants previously vaccinated with CD-JEV received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate 7 Days and 28 Days After Booster Dose</title>
          <description>Seroconversion rate is defined as the percentage of study participants with either:&#xD;
For participants who were seronegative at Baseline (defined as anti-JE neutralizing antibody titer of &lt; 1:10 assessed using PRNT-50 at Year 4, prior to booster vaccination): A change in serostatus from seronegative (anti-JE neutralizing antibody titer of &lt; 1:10) to positive (anti-JE neutralizing antibody titer ≥ 1:10)&#xD;
For participants who were seropositive at Baseline (defined as an anti-JE neutralizing antibody titer ≥1:10 assessed using PRNT-50 at Year 4, prior to booster vaccination): a 4-fold increase in anti-JE neutralizing antibody titer relative to Baseline anti-JE neutralizing antibody titer</description>
          <population>Participants who received the booster dose of CD-JEV and had at least one serology result 7 days or 28 days after the booster vaccination (ITT booster analysis set).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 days after booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="417"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" lower_limit="85.3" upper_limit="91.4"/>
                    <measurement group_id="O2" value="91.6" lower_limit="84.8" upper_limit="95.5"/>
                    <measurement group_id="O3" value="89.3" lower_limit="86.4" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days after booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="415"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" lower_limit="94.1" upper_limit="97.8"/>
                    <measurement group_id="O2" value="98.2" lower_limit="93.6" upper_limit="99.5"/>
                    <measurement group_id="O3" value="96.8" lower_limit="94.9" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference at 7 days post booster vaccination</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (Group A - B)</param_type>
            <param_value>-2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.0</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference at 28 days post booster vaccination</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference (Group A - B)</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT Ratio of Anti-JE Neutralizing Antibody Titers Between Post-Booster and Pre-Booster Vaccination</title>
        <description>To evaluate the magnitude of the increase in GMTs, the GMT ratio of anti-JE neutralizing antibody titers between post-booster vaccination and pre-booster vaccination was calculated for the following:&#xD;
GMT of anti-JE neutralizing antibodies at 7 days after booster vaccination to the Year 4, pre-booster GMT of anti-JE neutralizing antibodies&#xD;
GMT of anti-JE neutralizing antibodies at 28 days after booster vaccination to the Year 4, pre-booster GMT of anti-JE neutralizing antibodies</description>
        <time_frame>4 years after the initial vaccination (Study Day 365, pre-booster vaccination) and 7 and 28 days following booster vaccination (Study Days 372 and 393)</time_frame>
        <population>Participants who received the booster dose of CD-JEV and had at least one serology result 7 days or 28 days after the booster vaccination (ITT booster analysis set).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the new facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Group B: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the old facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Participants previously vaccinated with CD-JEV received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT Ratio of Anti-JE Neutralizing Antibody Titers Between Post-Booster and Pre-Booster Vaccination</title>
          <description>To evaluate the magnitude of the increase in GMTs, the GMT ratio of anti-JE neutralizing antibody titers between post-booster vaccination and pre-booster vaccination was calculated for the following:&#xD;
GMT of anti-JE neutralizing antibodies at 7 days after booster vaccination to the Year 4, pre-booster GMT of anti-JE neutralizing antibodies&#xD;
GMT of anti-JE neutralizing antibodies at 28 days after booster vaccination to the Year 4, pre-booster GMT of anti-JE neutralizing antibodies</description>
          <population>Participants who received the booster dose of CD-JEV and had at least one serology result 7 days or 28 days after the booster vaccination (ITT booster analysis set).</population>
          <units>ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 days after booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="417"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="14.2" upper_limit="18.5"/>
                    <measurement group_id="O2" value="22.5" lower_limit="17.5" upper_limit="28.9"/>
                    <measurement group_id="O3" value="17.3" lower_limit="15.4" upper_limit="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days after booster</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="415"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="524"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" lower_limit="23.3" upper_limit="28.7"/>
                    <measurement group_id="O2" value="35.9" lower_limit="29.4" upper_limit="43.9"/>
                    <measurement group_id="O3" value="27.7" lower_limit="25.3" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Immediate Reactions 30 Minutes Following Booster Vaccination</title>
        <description>The number of participants with at least one occurrence of an immediate reaction, including local, systemic, or unsolicited adverse event that occurred within 30 minutes of the booster vaccination.</description>
        <time_frame>30 minutes following booster vaccination (Study Day 365)</time_frame>
        <population>Participants who received the booster vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the new facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Group B: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the old facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Participants previously vaccinated with CD-JEV received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immediate Reactions 30 Minutes Following Booster Vaccination</title>
          <description>The number of participants with at least one occurrence of an immediate reaction, including local, systemic, or unsolicited adverse event that occurred within 30 minutes of the booster vaccination.</description>
          <population>Participants who received the booster vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any immediate reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited Local Reactions Occurring Within 7 Days of Booster Vaccination</title>
        <description>Participants were monitored for local reactions from 30 minutes through 7 days post booster vaccination. Local reactions (at the injection site) included the following:&#xD;
Ecchymosis (bruising)&#xD;
Erythema (redness)&#xD;
Edema (swelling)&#xD;
Induration (hardness)&#xD;
Pain/tenderness&#xD;
Local ecchymosis, erythema, edema, and induration were graded as follows:&#xD;
Grade 1: ≤ 2.5 cm in diameter&#xD;
Grade 2: &gt; 2.5 cm in diameter with &lt; 50% surface area of extremity involved&#xD;
Grade 3: ≥ 50% surface area of extremity involved OR ulceration OR secondary infection OR phlebitis OR sterile abscess OR drainage&#xD;
Grade 4: potentially life-threatening consequences&#xD;
Injection site pain/tenderness were graded as follows:&#xD;
Grade 1: causing no or minimal limitation in use of limb&#xD;
Grade 2: causing greater than minimal limitation of use of limb&#xD;
Grade 3: causing inability to perform usual social or functional activities&#xD;
Grade 4: inability to perform basic self-care OR hospitalization indicated.</description>
        <time_frame>From 30 minutes to 7 days following booster vaccination (Study Day 365 to 372)</time_frame>
        <population>Participants who received the booster vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the new facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Group B: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the old facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Participants previously vaccinated with CD-JEV received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Local Reactions Occurring Within 7 Days of Booster Vaccination</title>
          <description>Participants were monitored for local reactions from 30 minutes through 7 days post booster vaccination. Local reactions (at the injection site) included the following:&#xD;
Ecchymosis (bruising)&#xD;
Erythema (redness)&#xD;
Edema (swelling)&#xD;
Induration (hardness)&#xD;
Pain/tenderness&#xD;
Local ecchymosis, erythema, edema, and induration were graded as follows:&#xD;
Grade 1: ≤ 2.5 cm in diameter&#xD;
Grade 2: &gt; 2.5 cm in diameter with &lt; 50% surface area of extremity involved&#xD;
Grade 3: ≥ 50% surface area of extremity involved OR ulceration OR secondary infection OR phlebitis OR sterile abscess OR drainage&#xD;
Grade 4: potentially life-threatening consequences&#xD;
Injection site pain/tenderness were graded as follows:&#xD;
Grade 1: causing no or minimal limitation in use of limb&#xD;
Grade 2: causing greater than minimal limitation of use of limb&#xD;
Grade 3: causing inability to perform usual social or functional activities&#xD;
Grade 4: inability to perform basic self-care OR hospitalization indicated.</description>
          <population>Participants who received the booster vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/tenderness - Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Solicited Systemic Reactions Occurring Within 7 Days of Booster Vaccination</title>
        <description>Participants were monitored for systemic reactions from 30 minutes through 7 days post booster vaccination. Systemic reactions (general signs / symptoms) included the following:&#xD;
Fever&#xD;
Change in eating habits&#xD;
Diarrhea&#xD;
Sleepiness&#xD;
Irritability&#xD;
Unusual crying&#xD;
Vomiting&#xD;
Fever was graded as follows:&#xD;
Grade 1: 37.5 ℃ to 37.9 ℃&#xD;
Grade 2: 38.0 ℃ to 38.4 ℃&#xD;
Grade 3: 38.5 ℃ to 40.0 ℃&#xD;
Grade 4: &gt; 40.0 ℃&#xD;
Change in eating habits, diarrhea, sleepiness, irritability, unusual crying, vomiting were graded as follows:&#xD;
Grade 1: causing no or minimal interference with usual social or functional activities&#xD;
Grade 2: causing greater than minimal interference with usual social or functional activities&#xD;
Grade 3: causing inability to perform usual social or functional activities OR hospitalization indicated&#xD;
Grade 4: inability to perform basic self-care OR medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.</description>
        <time_frame>From 30 minutes to 7 days following booster vaccination (Study Day 365 to 372)</time_frame>
        <population>Participants who received the booster vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the new facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Group B: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the old facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Participants previously vaccinated with CD-JEV received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Systemic Reactions Occurring Within 7 Days of Booster Vaccination</title>
          <description>Participants were monitored for systemic reactions from 30 minutes through 7 days post booster vaccination. Systemic reactions (general signs / symptoms) included the following:&#xD;
Fever&#xD;
Change in eating habits&#xD;
Diarrhea&#xD;
Sleepiness&#xD;
Irritability&#xD;
Unusual crying&#xD;
Vomiting&#xD;
Fever was graded as follows:&#xD;
Grade 1: 37.5 ℃ to 37.9 ℃&#xD;
Grade 2: 38.0 ℃ to 38.4 ℃&#xD;
Grade 3: 38.5 ℃ to 40.0 ℃&#xD;
Grade 4: &gt; 40.0 ℃&#xD;
Change in eating habits, diarrhea, sleepiness, irritability, unusual crying, vomiting were graded as follows:&#xD;
Grade 1: causing no or minimal interference with usual social or functional activities&#xD;
Grade 2: causing greater than minimal interference with usual social or functional activities&#xD;
Grade 3: causing inability to perform usual social or functional activities OR hospitalization indicated&#xD;
Grade 4: inability to perform basic self-care OR medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.</description>
          <population>Participants who received the booster vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any systemic reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever - Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever - Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits - Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability - Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting - Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Unsolicited Adverse Events (AEs) and Serious Adverse Events (SAEs) Within 28 Days Following Booster Vaccination</title>
        <description>AEs were graded for severity according to the following:&#xD;
Grade 1 (Mild): Symptoms causing no or minimal interference with usual social and functional activities&#xD;
Grade 2 (Moderate): Symptoms causing greater than minimal interference with usual social and functional activities&#xD;
Grade 3 (Severe): Symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated&#xD;
Grade 4 (Potentially life-threatening): Symptoms causing inability to perform basic self-care functions OR medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.&#xD;
Relationship to study vaccine was based on the Clinician's assessment.&#xD;
A serious adverse event is defined as an AE that meets 1 of the following criteria:&#xD;
Death&#xD;
Life-threatening&#xD;
Requires hospitalization or prolongation of existing hospitalization&#xD;
Results in persistent disability&#xD;
Important medical event based on medical judgement</description>
        <time_frame>28 days following booster vaccination (Study Days 365 to 393)</time_frame>
        <population>Participants who received the booster vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the new facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Group B: CD-JEV</title>
            <description>Participants previously vaccinated with CD-JEV manufactured in the old facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Participants previously vaccinated with CD-JEV received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited Adverse Events (AEs) and Serious Adverse Events (SAEs) Within 28 Days Following Booster Vaccination</title>
          <description>AEs were graded for severity according to the following:&#xD;
Grade 1 (Mild): Symptoms causing no or minimal interference with usual social and functional activities&#xD;
Grade 2 (Moderate): Symptoms causing greater than minimal interference with usual social and functional activities&#xD;
Grade 3 (Severe): Symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated&#xD;
Grade 4 (Potentially life-threatening): Symptoms causing inability to perform basic self-care functions OR medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.&#xD;
Relationship to study vaccine was based on the Clinician's assessment.&#xD;
A serious adverse event is defined as an AE that meets 1 of the following criteria:&#xD;
Death&#xD;
Life-threatening&#xD;
Requires hospitalization or prolongation of existing hospitalization&#xD;
Results in persistent disability&#xD;
Important medical event based on medical judgement</description>
          <population>Participants who received the booster vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-threatening adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unrelated adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days after booster vaccination (Study Day 365 to 393)</time_frame>
      <desc>Adverse events are reported for all participants who received the CD-JEV booster vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A: CD-JEV</title>
          <description>Participants previously vaccinated with CD-JEV manufactured in the new facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
        </group>
        <group group_id="E2">
          <title>Group B: CD-JEV</title>
          <description>Participants previously vaccinated with CD-JEV manufactured in the old facility received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
          <description>Participants previously vaccinated with CD-JEV received a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine by subcutaneous injection four years after initial vaccination.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Mumps</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal scratch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gastric pH decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jorge Flores, MD</name_or_title>
      <organization>PATH</organization>
      <phone>(202) 822-0033</phone>
      <email>jeflores@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

